Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NTX-253 in Healthy Participants and Stable Schizophrenia
NCT07344948Phase 1Recruiting
- Sponsor
- Neurosterix
- Start
- Oct 2025
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NTX-253 in schizophrenia, sponsored by Neurosterix. Primary endpoints: Number of reported Adverse Events at Day 35, Number of Adverse Events of Special Interest at Day 35 and 7 more. Started Oct 2025; status: recruiting.
02
Drugs
NTX-253
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07344948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07344948.